NCT04651127 2026-03-10
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Sun Yat-sen University
Phase 1/2 Terminated
Clinical Trials
55 trialsNCT06975293 2026-03-05
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
STORM Therapeutics LTD
Phase 1/2 Recruiting
NCT07277322 2026-03-02
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
Icahn School of Medicine at Mount Sinai
Phase 1/2 Not yet recruiting
NCT07281716 2026-02-19
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Recruiting
NCT07281976 2026-02-12
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
NCT07392736 2026-02-06
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
Advenchen Laboratories, LLC
Phase 1/2 Recruiting
NCT05518045 2026-02-04
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
LaNova Medicines Limited
Phase 1/2 Active not recruiting
NCT06771622 2026-02-04
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited
Phase 1/2 Active not recruiting
NCT04284488 2026-01-08
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT05664971 2025-12-02
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Completed
NCT07258979 2025-12-02
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT07245901 2025-11-24
Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Not yet recruiting
NCT06462222 2025-09-29
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
Guangzhou Medical University
Phase 1/2 Active not recruiting
NCT06682780 2025-09-25
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT07169994 2025-09-12
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT06088004 2025-08-22
Phase â… /â…¡ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
Phase 1/2 Recruiting
NCT06208410 2025-07-25
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase 1/2 Recruiting
NCT07040228 2025-06-27
A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Phase 1/2 Recruiting
NCT05102006 2025-06-03
A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed
NCT04322006 2025-05-22
A Phase I/II Study of TJ004309 for Advanced Solid Tumor
TJ Biopharma Co., Ltd.
Phase 1/2 Active not recruiting
NCT04914286 2025-05-14
A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2 Completed
NCT05830539 2025-05-02
IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Completed
NCT06093438 2025-03-11
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2 Recruiting
NCT04785196 2025-02-26
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Ascentage Pharma Group Inc.
Phase 1/2 Recruiting
NCT05000684 2025-02-20
Study of JS004 Combined With Toripalimab for Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Completed
NCT05188664 2025-02-17
Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
LaNova Medicines Limited
Phase 1/2 Completed
NCT06038396 2025-01-29
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
RemeGen Co., Ltd.
Phase 1/2 Recruiting
NCT06139211 2024-12-20
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT05615974 2024-12-19
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT06117566 2024-11-25
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Shanghai Jiatan Pharmatech Co., Ltd
Phase 1/2 Recruiting
NCT06410703 2024-10-31
CAN1012 Combined With PD-1 in Patients With Solid Tumors
Canwell Biotech Limited
Phase 1/2 Recruiting
NCT06612632 2024-09-25
Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Recruiting
NCT06079112 2024-09-19
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT05955105 2024-05-21
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Innolake Biopharm
Phase 1/2 Recruiting
NCT06370754 2024-04-17
FD-IMPACT
Fudan University
Phase 1/2 Not yet recruiting
NCT05576961 2024-01-23
Safety and Efficacy of RX-af01 Combined With PD-1 Antibody
Sun Yat-sen University
Phase 1/2 Unknown
NCT03867370 2023-11-29
Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Terminated
NCT05580445 2023-11-22
Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer
Shouyao Holdings (Beijing) Co. LTD
Phase 1/2 Unknown
NCT05699811 2023-04-28
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT04856631 2022-12-19
A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT04481009 2022-12-12
A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
Phase 1/2 Completed
NCT03864211 2022-09-29
Thermal Ablation Followed by Immunotherapy for HCC
Xiangya Hospital of Central South University
Phase 1/2 Unknown
NCT05539118 2022-09-14
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
Xijing Hospital
Phase 1/2 Not yet recruiting
NCT05165849 2022-05-20
A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2 Withdrawn
NCT05341193 2022-04-22
PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 1/2 Unknown
NCT04058470 2022-04-14
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Sun Yat-sen University
Phase 1/2 Unknown
NCT05173142 2022-03-08
HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors
Hutchmed
Phase 1/2 Unknown
NCT02915432 2021-12-13
The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT05103917 2021-11-02
A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC
Abbisko Therapeutics Co, Ltd
Phase 1/2 Unknown
NCT04926532 2021-06-15
Toripalimab
Shanghai Zhongshan Hospital
Phase 1/2 Unknown